Clinical Perspective of Asthma & COPD

Question 1

These drugs are monoclonal antibodies against IL-5.

Answer 1

Mepolizumab, benralizumab

Question 2

True/False. Frequent SABA use is associated with a reduced bronchodilator response.

Answer 2

True - receptors become desensitized

Question 3

What is the MOA of Omalizumab?

Answer 3

IgG antibody against IgE that prevents activation of mast cells

Question 4

The term “blue bloater” is most associated with what disease?

Answer 4

Chronic bronchitis

Question 5

Roflumilast is a PDE-4 inhibitor. What is the clinical effect of this drug?

Answer 5

Reduces the number of COPD exacerbations

Question 6

What pulmonary function test is most useful in differentiating COPD and asthma?

Answer 6

Diffusing capacity (DLCO) - decreased in COPD

Question 7

When are ICS indicated in patients with COPD?

Answer 7

History of exacerbations requiring hospitalization

Question 8

What is the etiology of atopic/extrinsic asthma?

Answer 8

Allergic asthma, more common in males, positive family history

Question 9

Asthma symptoms are worse during the night and early morning. Why is this?

Answer 9

This is when histamine levels are highest and cortisol levels are lowest

Question 10

What is the etiology of non-atopic or intrinsic asthma?

Answer 10

Non-allergic asthma, more common in females, no family history

Question 11

This drug is used to treat COPD, but is associated with severe diarrhea. What is the MOA?

Answer 11

Roflumilast - PDE-4 inhibitor to increases cAMP

Question 12

A combination of LABAs and (LAMAs/ICS) are preferred in treating COPD?

Answer 12

LABAs + LAMAs –> ICS carry a risk of pneumonia in patients with COPD and are only used in cases of repeated exacerbations

Question 13

The term “pink puffer” is most associated with what disease?

Answer 13

Emphysema

Question 14

What is the MOA of dupliumab?

Answer 14

Monoclonal antibody against IL-4 & IL-13 that prevents B cell maturation and IgE release